GSK relaunches COPD patient site with blockbuster sales on the line

GlaxoSmithKline's ($GSK) new respiratory blockbuster hopefuls, Anoro and Breo, aren't quite where analysts thought they'd be by now. And with the pair slated to take the torch from aging giant Advair, Glaxo is taking their marketing seriously. As part of that effort, the British pharma has relaunched its COPD.com, a patient education and disease management site where COPD sufferers "are invited to take steps to strengthen their relationships with healthcare providers" and "work closely with their physician to develop an individualized COPD action plan," the company said. Release | More

Suggested Articles

​​​​​​​Baseball and allergy season are in full swing, and Houston Astros pitcher Justin Verlander knows both. He stars in GSK's new seasonal push.

PhRMA’s latest round of drug-cost ads defends a drugmaker favorite—the copay coupon—against new payer programs designed to thwart it.

Researchers plan to tackle issues related to accelerated approval, risk comprehension for new drugs, scientific versus promotional claims and TV ads.